Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

67%

10 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

5 recruiting3 with results

Enrollment Performance

Analytics

Phase 4
5(33.3%)
Phase 3
5(33.3%)
N/A
4(26.7%)
Phase 2
1(6.7%)
15Total
Phase 4(5)
Phase 3(5)
N/A(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT06008197Phase 3Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Role: lead

NCT06909565Phase 4Recruiting

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Role: collaborator

NCT07334834Not ApplicableRecruiting

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

Role: lead

NCT05284747Phase 4Active Not Recruiting

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Role: collaborator

NCT04807218Not ApplicableCompleted

Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot)

Role: lead

NCT06024746Phase 3Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Role: lead

NCT06033950Phase 3Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

Role: lead

NCT04400409Not ApplicableCompleted

Implementation of Vascular Care Team to Improve Medical Management of PAD Patients

Role: lead

NCT04655586Phase 2Completed

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

Role: collaborator

NCT02504216Phase 3Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Role: collaborator

NCT00822172Phase 4Completed

Evaluation of Cilostazol in Combination With L-Carnitine

Role: lead

NCT02350114Not ApplicableCompleted

An Observational Study of the Functional Capacity of Heart Failure

Role: collaborator

NCT00657514Phase 4Withdrawn

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Role: lead

NCT01825382Phase 4Completed

Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study

Role: collaborator

NCT00399919Phase 3Completed

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

Role: collaborator

All 15 trials loaded